Immunoprecise Antibodies Ltd
XTSX:IPA
EV/FCFF
Enterprise Value to FCFF
Enterprise Value to Free Cash Flow To Firm (EV/FCFF) ratio is a valuation multiple that compares the value of a company, debt included, to the amount of free cash flow available for all stakeholders. This metric is very similar to the EV/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.
Market Cap | EV/FCFF | ||||
---|---|---|---|---|---|
CA |
Immunoprecise Antibodies Ltd
XTSX:IPA
|
161.4m CAD | -11.7 | ||
US |
Thermo Fisher Scientific Inc
NYSE:TMO
|
229.3B USD | 36.5 | ||
US |
Danaher Corp
NYSE:DHR
|
187.7B USD | 35.5 | ||
US |
Agilent Technologies Inc
NYSE:A
|
43.9B USD | 27.1 | ||
US |
IQVIA Holdings Inc
NYSE:IQV
|
42.5B USD | 36 | ||
CH |
Lonza Group AG
SIX:LONN
|
37.9B CHF | -132.3 | ||
KR |
Samsung Biologics Co Ltd
KRX:207940
|
56T KRW | 98.4 | ||
US |
Mettler-Toledo International Inc
NYSE:MTD
|
32.3B USD | 37.7 | ||
US |
West Pharmaceutical Services Inc
NYSE:WST
|
26.6B USD | 67.5 | ||
IE |
ICON PLC
NASDAQ:ICLR
|
26.1B USD | 24.8 | ||
US |
Waters Corp
NYSE:WAT
|
20.8B USD | 43.8 |
EV/FCFF Forward Multiples
Forward EV/FCFF multiple is a version of the EV/FCFF ratio that uses forecasted free cash flow to firm for the EV/FCFF calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to firm forecasts for 1, 2, and 3 years ahead, respectively.